IMTX

Immatics N.V.

12.60 USD
+0.04 (+0.32%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Immatics N.V. stock is up 8.34% since 30 days ago. The next earnings date is Mar 19, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 February’s closed higher than January. In the last 5 Unusual Options Trades, there were 1 PUT, 4 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 Jan 19:46 19 Jul, 2024 5.00 PUT 830 830
03 Jan 19:47 19 Apr, 2024 7.50 CALL 72 23
09 Jan 17:00 19 Jul, 2024 12.50 CALL 150 25
16 Jan 14:55 19 Jan, 2024 10.00 CALL 160 1766
24 Jan 20:04 19 Apr, 2024 12.50 CALL 200 267

About Immatics N.V.

Immatics N.V. focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited.